Screener
Rhythm Pharmaceuticals, Inc. RYTM Single reportable segment — Commercial & medical affairs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rytm:CommercialAndMedicalExpenses.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Cost of sales | 7,157 | 3,648 |
| Global headcount expense | 58,653 | 34,868 |
| Preclinical, clinical and development expense | 18,511 | 19,960 |
| Commercial & medical affairs | 20,264 | 13,249 |
| Corporate, general & administrative | 7,888 | 7,983 |
| Other income (expense), net | (1,704) | (644) |
| Interest income (expense), net | (1,029) | (1,770) |
| Income taxes | 545 | 80 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported single reportable segment — commercial & medical affairs of $20.26M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs increased by 52.9% year-over-year, from $13.25M to $20.26M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs?
- Over 3 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs has grown at a 17.1% compound annual growth rate (CAGR), from $41.76M to $66.96M.
- What does single reportable segment — commercial & medical affairs mean?
- This metric measures the expenditures related to marketing, sales force support, and medical education initiatives for the company's commercialized products. It reflects the investment in building brand awareness, physician education, and patient access programs. Tracking this helps evaluate the cost-effectiveness of the company's go-to-market strategy.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s single reportable segment — commercial & medical affairs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude